Top in cardiology: More guidance on sexual health needed; Zerlasiran lowers lipoprotein(a)
Click Here to Manage Email Alerts
A survey of patients with CVD in Sweden revealed that of 78% of respondents cited a desire for information on sexual health, yet only 5% reported receiving this information.
“A large number of patients, independent of age and gender, really feel that their condition is [affecting] their sexual health and that they currently do not get enough information and support,” Tiny Jaarsma, PhD, professor of nursing at Linköping University in Sweden, told Healio.
Patients reported wanting to discuss adverse events of medications, erectile dysfunction, impact of sex on relationships, anxiety before sex and pain during sex.
“[We need] more studies on how to equip patients better to be able to ask their questions and health care professionals on how to bring up the subject in a professional and safe way,” Jaarsma said.
It was the top story in cardiology last week.
In another top story, results from the phase 2 ALPACAR trial demonstrated that Zerlasiran, a novel injectable small interfering RNA molecule, lowered lipoprotein(a) by more than 80% compared with placebo at 36 weeks.
Read these and more top stories in cardiology below:
‘Please talk about it’: Patients with heart disease want more guidance on sexual health
Results from a new survey highlight a gap between patients’ information needs about sexual health and the actual support provided by health care professionals. Read more.
Novel injectable agent lowers Lp(a) by more than 80% at 36 weeks
Zerlasiran, a novel injectable small interfering RNA molecule, lowered lipoprotein(a) by more than 80% compared with placebo at 36 weeks, according to the results of the ALPACAR trial. Read more.
Acoramidis approved to reduce CV death, hospitalization for cardiac amyloidosis
BridgeBio Pharma announced that acoramidis, its small molecule stabilizer of transthyretin, has been approved by the FDA for the reduction of cardiovascular death and hospitalization in patients with transthyretin amyloid cardiomyopathy. Read more.
Elevated CVD risk with type 2 diabetes may be traceable to diabetes development factors
People with type 2 diabetes had twice the number of CVD events vs. matched counterparts, with events starting 3 decades before diagnosis, suggesting their elevated CVD risk may be attributable to factors tied to diabetes development. Read more.
Lesbian, gay, bisexual veterans face higher odds for prevalent ASCVD vs. straight peers
Lesbian, gay and bisexual U.S. veterans had significantly higher odds for prevalent atherosclerotic CVD compared with their heterosexual peers, according to findings published in the Journal of the American Heart Association. Read more.